

2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Report

https://marketpublishers.com/r/2F66047D8B7EN.html

Date: August 2018

Pages: 136

Price: US\$ 4,660.00 (Single User License)

ID: 2F66047D8B7EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Benign Prostatic Hyperplasia (BPH) Drugs market for 2018-2023.

Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59



years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market's growth.

Over the next five years, LPI(LP Information) projects that Benign Prostatic Hyperplasia (BPH) Drugs will register a xx% CAGR in terms of revenue, reach US\$ xx million by 2023, from US\$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia (BPH) Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

5-Alpha-Reductase Inhibitors

Segmentation by application:

Men

Women

This report also splits the market by region:

Americas

United States



	Canada	
	Mexico	
	Brazil	
APAC		
	China	
	Japan	
	Korea	
	Southeast Asia	
	India	
	Australia	
Europe		
	Germany	
	France	
	UK	
	Italy	
	Russia	
	Spain	
Middle East & Africa		
	Egypt	



South Africa

Israel

Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market

as a whole. It also analyzes key emerging trends and their impact on present and future

development.



RESEARCH OBJECTIVES

To study and analyze the global Benign Prostatic Hyperplasia (BPH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.

To understand the structure of Benign Prostatic Hyperplasia (BPH) Drugs market by identifying its various subsegments.

Focuses on the key global Benign Prostatic Hyperplasia (BPH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Benign Prostatic Hyperplasia (BPH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Benign Prostatic Hyperplasia (BPH) Drugs submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.



Contents

2018-2023 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS CONSUMPTION MARKET REPORT

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Research Objectives
- 1.3 Years Considered
- 1.4 Market Research Methodology
- 1.5 Economic Indicators
- 1.6 Currency Considered

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2023
 - 2.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region
- 2.2 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type
 - 2.2.1 Alpha-Blocker
 - 2.2.2 Phosphodiesterase Type-5 Inhibitors
 - 2.2.3 5-Alpha-Reductase Inhibitors
- 2.3 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
- 2.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)
- 2.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2013-2018)
- 2.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2013-2018)
- 2.4 Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application
 - 2.4.1 Men
 - 2.4.2 Women
- 2.5 Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
- 2.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)
- 2.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value and Market Share by Application (2013-2018)
- 2.5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application



(2013-2018)

3 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY PLAYERS

- 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players
- 3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016-2018)
- 3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016-2018)
- 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players
- 3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Players (2016-2018)
- 3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players (2016-2018)
- 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players
- 3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
- 3.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution and Sales Area by Players
- 3.4.2 Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS BY REGIONS

- 4.1 Benign Prostatic Hyperplasia (BPH) Drugs by Regions
 - 4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions
- 4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions
- 4.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
- 4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
- 4.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth
- 4.5 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth

5 AMERICAS



- 5.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
- 5.1.1 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
- 5.1.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
- 5.2 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
- 5.3 Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

- 6.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries
- 6.1.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
- 6.1.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
- 6.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
- 6.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

- 7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Countries
- 7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
- 7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
- 7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
- 7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
- 7.4 Germany



- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 7.9 Spain
- 7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs by Countries
- 8.1.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018)
- 8.1.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018)
- 8.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type
- 8.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers and Impact
 - 9.1.1 Growing Demand from Key Regions
 - 9.1.2 Growing Demand from Key Applications and Potential Industries
- 9.2 Market Challenges and Impact
- 9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

- 10.1 Sales Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
- 10.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
- 10.3 Benign Prostatic Hyperplasia (BPH) Drugs Customer



11 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS MARKET FORECAST

- 11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2018-2023)
- 11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions
- 11.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Regions (2018-2023)
- 11.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Regions (2018-2023)
 - 11.2.3 Americas Consumption Forecast
 - 11.2.4 APAC Consumption Forecast
 - 11.2.5 Europe Consumption Forecast
- 11.2.6 Middle East & Africa Consumption Forecast
- 11.3 Americas Forecast by Countries
 - 11.3.1 United States Market Forecast
 - 11.3.2 Canada Market Forecast
 - 11.3.3 Mexico Market Forecast
- 11.3.4 Brazil Market Forecast
- 11.4 APAC Forecast by Countries
 - 11.4.1 China Market Forecast
 - 11.4.2 Japan Market Forecast
 - 11.4.3 Korea Market Forecast
 - 11.4.4 Southeast Asia Market Forecast
 - 11.4.5 India Market Forecast
- 11.4.6 Australia Market Forecast
- 11.5 Europe Forecast by Countries
- 11.5.1 Germany Market Forecast
- 11.5.2 France Market Forecast
- 11.5.3 UK Market Forecast
- 11.5.4 Italy Market Forecast
- 11.5.5 Russia Market Forecast
- 11.5.6 Spain Market Forecast
- 11.6 Middle East & Africa Forecast by Countries
 - 11.6.1 Egypt Market Forecast
 - 11.6.2 South Africa Market Forecast
 - 11.6.3 Israel Market Forecast
- 11.6.4 Turkey Market Forecast



- 11.6.5 GCC Countries Market Forecast
- 11.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Type
- 11.8 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecast by Application

12 KEY PLAYERS ANALYSIS

- 12.1 Astellas Pharma
 - 12.1.1 Company Details
 - 12.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue,

Price and Gross Margin (2016-2018)

- 12.1.4 Main Business Overview
- 12.1.5 Astellas Pharma News
- 12.2 Eli Lilly
 - 12.2.1 Company Details
 - 12.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
- 12.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.2.4 Main Business Overview
 - 12.2.5 Eli Lilly News
- 12.3 GlaxoSmithKline
 - 12.3.1 Company Details
 - 12.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
- 12.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue,

Price and Gross Margin (2016-2018)

- 12.3.4 Main Business Overview
- 12.3.5 GlaxoSmithKline News
- 12.4 Sanofi
 - 12.4.1 Company Details
 - 12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
- 12.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
 - 12.4.4 Main Business Overview
 - 12.4.5 Sanofi News
- 12.5 ADC Therapeutics
 - 12.5.1 Company Details
 - 12.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
- 12.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)



- 12.5.4 Main Business Overview
- 12.5.5 ADC Therapeutics News
- 12.6 Bayer HealthCare
 - 12.6.1 Company Details
 - 12.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue,

Price and Gross Margin (2016-2018)

- 12.6.4 Main Business Overview
- 12.6.5 Bayer HealthCare News
- 12.7 Bristol-Myers Squibb
 - 12.7.1 Company Details
 - 12.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales,

Revenue, Price and Gross Margin (2016-2018)

- 12.7.4 Main Business Overview
- 12.7.5 Bristol-Myers Squibb News
- 12.8 Valeant Pharmaceuticals
 - 12.8.1 Company Details
 - 12.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales,

Revenue, Price and Gross Margin (2016-2018)

- 12.8.4 Main Business Overview
- 12.8.5 Valeant Pharmaceuticals News
- 12.9 Endo Pharmaceuticals
 - 12.9.1 Company Details
 - 12.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales,

Revenue, Price and Gross Margin (2016-2018)

- 12.9.4 Main Business Overview
- 12.9.5 Endo Pharmaceuticals News
- 12.10 Foresee Pharmaceuticals
 - 12.10.1 Company Details
 - 12.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
 - 12.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales,

Revenue, Price and Gross Margin (2016-2018)

- 12.10.4 Main Business Overview
- 12.10.5 Foresee Pharmaceuticals News

13 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Benign Prostatic Hyperplasia (BPH) Drugs

Table Product Specifications of Benign Prostatic Hyperplasia (BPH) Drugs

Figure Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered

Figure Market Research Methodology

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate 2013-2023 (K MT)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate 2013-2023 (\$ Millions)

Table Benign Prostatic Hyperplasia (BPH) Drugs Consumption CAGR by Region 2013-2023 (\$ Millions)

Figure Product Picture of Alpha-Blocker

Table Major Players of Alpha-Blocker

Figure Product Picture of Phosphodiesterase Type-5 Inhibitors

Table Major Players of Phosphodiesterase Type-5 Inhibitors

Figure Product Picture of 5-Alpha-Reductase Inhibitors

Table Major Players of 5-Alpha-Reductase Inhibitors

Table Global Consumption Sales by Type (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2013-2018) (\$ million)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2013-2018) (\$ Millions)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Type (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2013-2018)

Figure Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Men

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Men (2013-2018) (K MT)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Men (2013-2018) (\$ Millions)

Figure Global Men YoY Growth (\$ Millions)



Figure Benign Prostatic Hyperplasia (BPH) Drugs Consumed in Women

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Women (2013-2018) (K MT)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Women (2013-2018) (\$ Millions)

Figure Global Women YoY Growth (\$ Millions)

Table Global Consumption Sales by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2013-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Application (2013-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Players (2016-2018) (K MT)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players (2016-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players in 2016

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Players in 2017

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Players (2016-2018) (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players (2016-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players in 2016

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Players in 2017

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players (2016-2018)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players in 2017 Table Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base



Distribution and Sales Area by Players

Table Players Benign Prostatic Hyperplasia (BPH) Drugs Products Offered

Table Benign Prostatic Hyperplasia (BPH) Drugs Concentration Ratio (CR3, CR5 and CR10) (2016-2018)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Regions 2013-2018 (K MT)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2013-2018

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Regions 2013-2018

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value by Regions 2013-2018 (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2013-2018

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Regions 2013-2018

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 (\$ Millions)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 (\$ Millions) Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 (\$ Millions) Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2013-2018 (K MT)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2013-2018 (\$ Millions)

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) (\$ Millions)

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by



Countries (2013-2018)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)

Table Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) (\$ Millions)

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017



Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)

Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017

Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure China Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure India Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by



Countries (2013-2018)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) (\$ Millions)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)

Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017

Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure France Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure France Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)



Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Countries (2013-2018) (K MT)

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries (2013-2018)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Countries in 2017

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value by Countries (2013-2018) (\$ Millions)

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries (2013-2018)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share by Countries in 2017

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type (2013-2018) (K MT)

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type (2013-2018)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Type in 2017

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Application (2013-2018) (K MT)

Table Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application (2013-2018)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share by Application in 2017

Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth



2013-2018 (K MT)

Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth 2013-2018 (K MT)

Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value Growth 2013-2018 (\$ Millions)

Table Benign Prostatic Hyperplasia (BPH) Drugs Distributors List

Table Benign Prostatic Hyperplasia (BPH) Drugs Customer List

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Growth Rate Forecast (2018-2023) (K MT)

Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Value Growth Rate Forecast (2018-2023) (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Countries (2018-2023) (K MT)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Forecast by Regions

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Countries (2018-2023) (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Regions

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Americas Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)



Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure China Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Korea Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT) Figure India Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Australia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure France Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure France Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)



Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT) Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT) Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions) Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Consumption 2018-2023 (K MT)

Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Value 2018-2023 (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Type (2018-2023) (K MT)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Type (2018-2023)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Type (2018-2023) (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Type (2018-2023)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Application (2018-2023) (K MT)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Share Forecast by Application (2018-2023)



Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Forecast by Application (2018-2023) (\$ Millions)

Table Global Benign Prostatic Hyperplasia (BPH) Drugs Value Market Share Forecast by Application (2018-2023)

Table Astellas Pharma Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Eli Lilly Basic Information, Manufacturing Base, Sales Area and Its Competitors Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018) Table GlaxoSmithKline Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Sanofi Basic Information, Manufacturing Base, Sales Area and Its Competitors Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018) Table ADC Therapeutics Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Bayer HealthCare Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Bristol-Myers Squibb Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue,



Price and Gross Margin (2016-2018)

Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Valeant Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Endo Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)

Table Foresee Pharmaceuticals Basic Information, Manufacturing Base, Sales Area and Its Competitors

Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2016-2018)

Figure Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Market Share (2016-2018)



I would like to order

Product name: 2018-2023 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Report

Product link: https://marketpublishers.com/r/2F66047D8B7EN.html

Price: US\$ 4,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/2F66047D8B7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms